Kane Biotech Announces Publication in Frontiers in Antibiotics Highlighting Advancements in Treating Antibiotic Tolerant Biofilms

Executive Summary

• Frontiers in Antibiotics published a peer‑reviewed article co‑authored by Kane Biotech and University of Manitoba researchers demonstrating that revyve Antimicrobial Wound Gel effectively eradicates antibiotic‑tolerant Staphylococcus aureus and Pseudomonas aeruginosa biofilms in vitro and ex vivo.
• The study showed large log‑scale reductions in bacterial counts, often below detectable limits within 24–72 hours after treatment, highlighting revyve’s potential as an advanced wound‑care solution for chronic, biofilm‑laden wounds.
• The publication reinforces Kane Biotech’s market positioning and supports ongoing commercialization of revyve across wound and burn care markets (U.S. FDA 510(k) cleared; Health Canada approved).

Key Details

• Article Title: “Efficacy of a Novel Thermo‑Reversible Wound Gel Against Antibiotic Tolerant Biofilm.”
• Journal: Frontiers in Antibiotics (peer‑reviewed, open‑access).
• Authors: Dr. Jeyachchandran Visvalingam (Internal R&D Leader, Kane Biotech) – lead author; Dr. Sarvesh Logsetty (burn and trauma surgeon, University of Manitoba) – co‑author.
• Key Findings:
• revyve Antimicrobial Wound Gel demonstrated strong activity against mature antibiotic‑tolerant biofilms of S. aureus and P. aeruginosa.
• In both in‑vitro and ex‑vivo models, the gel eliminated these biofilms after prior antibiotic exposure that induced high tolerance levels.
• Post‑treatment bacterial counts were reduced by several log units, frequently falling below detection limits within 24–72 hours.
• Regulatory Status: revyve Antimicrobial Wound Gel is U.S. FDA 510(k) cleared and Health Canada approved (also available as a spray and skin/wound cleanser).
• Strategic Impact: The publication provides third‑party scientific validation of Kane’s core technology, supporting its commercialization strategy in wound and burn care markets.
• CEO Comment: “Having our research published … reinforces the strength of our technology and supports our mission to bring advanced, biofilm‑targeted solutions to patients.” – Dr. Robert Huizinga, Interim CEO.

Notable Quotes

“This peer‑reviewed journal is recognized for its rigorous scientific standards and transparent review process. This publication reinforces the strength of our technology and supports our mission to bring advanced, biofilm‑targeted solutions to patients.” – Dr. Robert Huizinga, Interim CEO, Kane Biotech

All boilerplate, forward‑looking disclaimer text and distribution list information have been omitted for clarity.